General Information

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. Our lead product, XHANCE, is a therapeutic utilizing our proprietary Breath Powered exhalation delivery system, or EDS, that delivers a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Employees: 35
Founded: 2010
Contact Information
Address 1020 Stony Hill Road, Suite 300, Yardley, Pennsylvania 19067<
Phone Number (267) 364-3500
Web Address http://www.optinose.com
View Prospectus: OptiNose
Financial Information
Market Cap $566.2mil
Revenues $0 mil (last 12 months)
Net Income $-42.8 mil (last 12 months)
IPO Profile
Symbol OPTN
Exchange NASDAQ
Shares (millions): 7.5
Price range $16.00 - $16.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Jefferies/ Piper Jaffray/ BMO Capital Markets/ RBC Capital Markets
CO-Managers -
Expected To Trade: 10/13/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change